EUVIMEDScopri EUVIMED
Open access · CC BY-NC 3.0

Enhanced Everolimus Delivery: Development and Evaluation of a Nanosuspension Formulation

Qiao Zeng iD, Jie Chen, Han Zhang, Wenying Yu iD, Haonan Xu, Qiao Wang iD, Zhan Tang

International Journal of Nanomedicine · 2025

DOI: 10.2147/ijn.s562002 ↗

At a glance

Journal article in International Journal of Nanomedicine, 2025. Written by Qiao Zeng and 6 co-authors. Institution: School of Pharmacy, Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China. Major MEDLINE topics: Everolimus, Nanoparticles, Angiogenesis Inhibitors. Cited 2 times so far (Crossref); 50 references. The full text is freely available (open access, CC BY-NC 3.0).

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Purpose

To develop everolimus-loaded nanosuspensions (EV-sus) for the in vitro and in vivo corneal neovascularization (CNV) treatment.

Results

Everolimus was encapsulated into nanosuspensions using a solvent volatilization technique. The developed nanosuspensions exhibited a drug concentration of 0.96 mg·mL-1, an average particle size of 141.0 ± 1.0 nm, and a zeta potential of -12.2 ± 0.4 mV. C6-labeled EV-sus uptake by Human Corneal Epithelial Cells-Transformed (HCE-T) was time-dependent, energy-dependent, and involved multiple endocytic pathways, including caveolae- and lipid raft-mediated endocytosis, clathrin-mediated endocytosis, and caveolae-mediated endocytosis. The nanosuspensions exhibited efficacy in inhibiting VEGF-induced proliferation, migration, and tube formation in Human Umbilical Vein Endothelial Cells (HUVECs). According to RT-qPCR, the in vivo CNV model showed that EV-sus effectively reduced neovascularization, decreased vascular length and area, and diminished the expression of IL-1, IL-6, MMP-9, VEGF, and TNF-α. Additionally, the rabbit eye irritation test confirmed the safety and tolerability of the formulation.

Conclusion

These findings indicate that EV-sus might be an effective therapy for corneal neovascularization. The formulation exhibits excellent biocompatibility, efficient cellular uptake, and robust anti-angiogenic activity, suggesting its suitability for ocular administration and the potential to mitigate CNV progression with minimal irritation.

Subjects

MeSH terms (MEDLINE)

EverolimusNanoparticlesAngiogenesis InhibitorsHumansAnimalsRabbitsCorneal NeovascularizationHuman Umbilical Vein Endothelial CellsParticle SizeSuspensionsCell ProliferationCell MovementVascular Endothelial Growth Factor AEndocytosis

Author keywords

HCE-TsHUVECscorneal neovascularizationeverolimusnanosuspensions

Substances

EverolimusSuspensionsAngiogenesis InhibitorsVascular Endothelial Growth Factor A

Authors and institutions

  • School of Pharmacy, Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China.
  • Key Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China.

ORCID profiles: Qiao Zeng, Wenying Yu, Qiao Wang

Cite

APA

Zeng, Q., Chen, J., Zhang, H., Yu, W., Xu, H., Wang, Q., & Tang, Z. (2025). Enhanced Everolimus Delivery: Development and Evaluation of a Nanosuspension Formulation. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s562002

Vancouver

Zeng Q, Chen J, Zhang H, Yu W, Xu H, Wang Q, et al. Enhanced Everolimus Delivery: Development and Evaluation of a Nanosuspension Formulation. International Journal of Nanomedicine. 2025. doi:10.2147/ijn.s562002

BibTeX
@article{Zeng2025,
  author = {Zeng, Qiao and Chen, Jie and Zhang, Han and Yu, Wenying and Xu, Haonan and Wang, Qiao and Tang, Zhan},
  title = {Enhanced Everolimus Delivery: Development and Evaluation of a Nanosuspension Formulation},
  journal = {International Journal of Nanomedicine},
  year = {2025},
  doi = {10.2147/ijn.s562002}
}
Start for free →